The total number of records retrieved from this search are 20. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_608	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma epithelial cell line	Cell lineU2OS (telomerase-negative)	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result96% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_611	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma epithelial cell line	Cell lineU2OS (telomerase-negative)	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result94% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_614	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma epithelial cell line	Cell lineU2OS (telomerase-negative)	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result92% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_617	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma epithelial cell line	Cell lineU2OS (telomerase-negative)	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result90% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_4112	Virus nameAdenovirus	Virus strainAd-CCL20-CD40L	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of CCL20 and CD40L gene near by TERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomevirus expressing CCL20 chemokine gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result95% cell survival after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26208317
IDOV_4116	Virus nameAdenovirus	Virus strainAd-CCL20-CD40L	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of CCL20 and CD40L gene near by TERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomevirus expressing CCL20 chemokine gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell survival after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26208317
IDOV_4120	Virus nameAdenovirus	Virus strainAd-CCL20-CD40L	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of CCL20 and CD40L gene near by TERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomevirus expressing CCL20 chemokine gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell survival after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26208317
IDOV_4124	Virus nameAdenovirus	Virus strainAd-CCL20-CD40L	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of CCL20 and CD40L gene near by TERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomevirus expressing CCL20 chemokine gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result95% cell survival after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26208317
IDOV_4933	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4934	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4935	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4936	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4937	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4938	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4939	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4940	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4941	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4942	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4943	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4944	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineATCC	Origin of cell lineHuman osteosarcoma cell line	Cell lineU2OS	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859